QUE Oncology is a dynamic brand that is dedicated to unleashing the immense potential of their flagship product, Q-122. This groundbreaking solution is specifically designed to provide a non-hormonal remedy for postmenopausal women experiencing moderate to severe vasomotor symptoms such as hot flashes and night sweats. Additionally, Q-122 is also targeted for cancer patients undergoing hormone therapy.

Established in 2013, QUE emerged as a result of a strategic partnership between Emory University and UniQuest, the research commercialization company of the University of Queensland (UQ). Supported by leading venture capital groups, including Australia's Medical Research Commercialization Fund (MRCF) and Uniseed, QUE is at the forefront of clinical stage research. With an impressive track record, QUE recently accomplished a randomized, double-blind, placebo-controlled Phase 2 trial across multiple countries, namely Australia, New Zealand, and the US.

The trial not only met its primary efficacy endpoint but also demonstrated an exceptionally well-tolerated profile. Rest assured that QUE Oncology is committed to revolutionizing the treatment landscape for vasomotor symptoms while prioritizing safety and efficacy